Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

Thermo Fisher launches NGS hybrid capture assay

June 2025—Thermo Fisher Scientific has introduced the One Lambda HybriType HLA Plus Typing Flex kit, a next-generation sequencing hybrid capture assay featuring a probe-based design that optimizes read balance and uniformity, potentially mitigating allele dropout. The assay is designed to provide flexibility in testing configuration and coverage, supporting human leukocyte antigen class I and II genotyping analysis across various sample types, including whole blood and buccal swabs. It has a turnaround time of less than 5.5 hours, and the hands-on time is less than 2.5 hours. Data for the assay are analyzed using the company’s Type­Stream Visual NGS analysis software. The kit is for research use only.

Dr. Jonathan Epstein joins Advanced Uropathology

June 2025—Advanced Uropathology, a division of Integrated Medical Professionals, announced that urologic pathologist Jonathan Epstein, MD, has joined its team. Physicians, hospitals, and laboratories can now refer specimens directly to Dr. Epstein, who will provide second opinions and expert interpretations of complex urologic pathology cases.

Sysmex adds XQ-320 to its line of three-part diff analyzers

June 2025—Sysmex America announced the expansion of its three-part differential automated hematology analyzer line with the XQ-320 for CBC testing. The XQ-320 has a throughput of up to 70 samples per hour, provides results in less than 60 seconds, and is the company’s first three-part differential analyzer that includes BeyondCare Quality Monitor. The analyzer features 17 parameters including an absolute neutrophil count, optional manual discrimination within histograms for challenging samples, robust flagging, and a low aspiration volume of 16 μL. It requires minimal weekly maintenance and offers a quick shutdown and automatic wake-up function.

Techcyte, Aiforia collaborate to advance AI-powered DP

June 2025—Techcyte and Aiforia announced a strategic partnership to accelerate the adoption of AI-driven workflows in anatomic pathology laboratories. The partnership brings together Techcyte’s Fusion digital pathology platform and Aiforia’s AI-powered diagnostic algorithms, beginning with the Aiforia breast cancer suite. The companies say the partnership will continue to drive innovation in digital pathology, cancer diagnostics, and more with an expanding portfolio of AI applications.

Qiagen gets clearance for second QIAstat-Dx mini GI panel

June 2025—Qiagen announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. The panel focuses on bacterial infections covering Campylobacter, Salmonella, Shiga-like toxin-producing E. coli, Shigella, and Yersinia enterocolitica. It is designed to complement the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers Campylobacter, Salmonella, STEC, Shigella, and norovirus. The panel runs on the QIAstat-Dx system and delivers results in about one hour with less than one minute of hands-on time.

Vitro appoints Biocare Medical as exclusive U.S. distributor

May 2025—Vitro announced it has appointed Biocare Medical (Pacheco, Calif.) as the exclusive distributor of its NeoPath Pro automated staining instrument in the United States. NeoPath Pro is a high-throughput platform with a 42-slide capacity, supporting immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization. The instrument was launched at the USCAP annual meeting in Boston, March 22–27. Vitro is headquartered in Spain.

Vitestro collaborates with Northwestern Medicine

May 2025—Northwestern Medicine and Vitestro announced a multiyear collaboration to advance automation in phlebotomy. As part of the collaboration, Northwestern Medicine will participate in a multicenter clinical trial validating the performance and safety of Vitestro’s Aletta, an autonomous robotic phlebotomy device. The goal of the study is to generate key clinical evidence to support the adoption of automated phlebotomy as a scalable solution for U.S. hospital and outpatient blood draw centers.

Bio-Rad gets EU QMS certificate for 40 QC products

May 2025—Bio-Rad Laboratories has received the EU quality management systems certificate under IVDR regulation (EU) 2017/746, enabling the CE-IVDR marking of 40 Exact Diagnostics infectious disease molecular quality controls. The controls are formulated with whole organisms in relevant matrices to simulate patient specimens. This design aims to ensure that the controls undergo the same workflow and process challenges as patient specimens during routine testing.

Revvity gets FDA approval for automated TB test

May 2025—Revvity announced that the FDA has approved the Auto-Pure 2400 liquid handling platform with the T-Spot.TB test, for in vitro diagnostic use. The Auto-Pure 2400 tests up to 24 samples per run and completes day-one T-Spot.TB workflows in less than three and a half hours.

MARKETPLACE

TRENDING